Analizzatori ematologici differenziali a 3 o 5 o 7 parti: La matrice decisionale completa per oltre 50 scenari clinici
Procurement teams spend thousands analyzing analyzer specifications, yet 73% still choose 5-part systems as the “safe middle ground.” But here’s what they don’t realize: 45% of the clinical scenarios they actually encounter demand 7-part capability. This critical mismatch between purchasing decisions and diagnostic requirements creates blind spots in patient care, missed early diagnoses, and suboptimal […]










